Circulating levels of PYY are increased in individuals with bile acid diarrhoea
Clicks: 6
ID: 322320
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.5
/100
6 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #66 of 367 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 367 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Bile acid diarrhoea (BAD) is a chronic disease caused by a disturbance of the enterohepatic circulation resulting in an abundance of bile acids in the colon, which in turn causes diarrhoea. Since bile acids stimulate the secretion of the hormone peptide YY (PYY), we investigated PYY levels in plasma samples from earlier studies enrolling patients with BAD and healthy volunteers. METHODS: We analysed total PYY in 1) a case-control study comparing individuals with BAD with matched healthy controls during acute administration of the bile acid sequestrant colesevelam and placebo; 2) a randomised controlled trial comparing the treatment effects of colesevelam and the glucagon-like peptide 1 (GLP-1) analogue liraglutide on bowel movements in individuals with BAD; and 3) a sequestrant study investigating the effect of treatment cessation in patients with BAD. We also investigated the PYY/GLP-1 ratios along the intestines of healthy individuals based on mRNA expression and immunohistochemistry. RESULTS: Individuals with BAD had higher fasting plasma PYY levels compared with controls but similar postprandial increments in the two groups. Symptom-alleviating treatment of BAD with sequestrants or liraglutide resulted in a decline of fasting PYY levels. Fasting PYY levels correlated positively with 7α-hydroxy-4-cholesten-3-one (C4) and plasma total bile acids. Finally, the PYY/GLP-1 ratio increased along the intestine with the highest ratios observed in the colon. CONCLUSION: Collectively, these results suggest a role for PYY as a marker for BAD pathophysiology and warrant further studies into the role of PYY in BAD and other diarrhoeal diseases.
| Reference Key |
openalex_W7170396819
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Andreas H. Lange, Martin L. Kårhus, Christopher Bannon, JULIE FORMAN, Frank Reimann, Fiona M. Gribble, Bolette Hartmann, Jens J Holst, Asger Lund, Knop Frf, Anne‐Marie Ellegaard |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag295
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.